Funding for this research was provided by:
Fonds De La Recherche Scientifique - FNRS (7463012F)
Fonds Léon Fredericq
Received: 29 October 2020
Accepted: 7 February 2021
First Online: 19 February 2021
Ethics approval and consent to participate
: Ethical Committee of the University of Liège approved the protocols used for animal studies under the references # 736. There were no clinical samples in this study.
: Not applicable.
: DC is the founder of Aquilon Pharmaceuticals, received speaker fees from AstraZeneca, Boehringer-Ingelheim, Chiesi and GSK and received consultancy fees from AstraZeneca, Boehringer-Ingelheim, Chiesi and Sanofi for the participation to advisory boards. None of these activities have any connection with oncology or development of drugs in the field of oncology.